Johnson & Johnson Stock News

Johnson & Johnson said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions SPRING HOUSE, Pa. , Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular propert...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.

Johnson & Johnson (JNJ 1.23%) is forecast to increase its free cash flow significantly over the next five years and beyond.

Equity markets have been volatile over the past week as some of the industry leaders in artificial intelligence (AI) -- which make up a large percentage of indexes like the Nasdaq Composite -- have been encountering stiff competition out of China.

Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the top ten Dow Dogs by February 2026, with Merck leading at $376.03. Five stocks, including Verizon and Merck, are close to meeting the dogcatcher ideal, with prices within 67.5% of their annual divid...

The Dow Jones Industrial Average (^DJI -0.99%) may be the most elite club in the stock market.